- Stocks
- Pharma & Healthcare
- Nath Bio-Genes (India)
Nath Bio-Genes (India) share price
NSE: NATHBIOGENPharma & HealthcareAgricultural Inputs
Nath Bio-Genes (India) at a glance
Nath Bio-Genes (India) (NSE: NATHBIOGEN) closed at ₹132.60 on 22 Oct 2026, up 0.76% on the day. With a market capitalisation of ₹252 Cr, it ranks 2138th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Agricultural Inputs.
At its last close the stock traded at 6.3× trailing earnings, against a return on equity of 6.1% in FY26. Over the past year the share price has fallen 23.0%. Its 52-week range is ₹126.15 (30 Mar 2026) to ₹204.00 (30 Apr 2026); the last close is 35.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹328 Cr (+15.8% year on year) and net profit ₹32 Cr (−13.5%), on a consolidated basis. Promoters held 45.60% of the company as of 30 Jun 2026; 13.78% of promoter shares were pledged.
Key numbers
- Market cap
- ₹252 CrRank 2138 on NSE
- P/E (trailing)
- 6.3×
- Price to book
- 0.36×FY26
- EPS (TTM)
- ₹18.43to Q1 FY27
- ROE
- 6.1%FY26
- ROCE
- 8.0%FY26
- Debt to equity
- 0.2FY26
- Net profit margin
- 9.4%FY26
- Book value / share
- ₹358.06FY26
- 52-week high
- ₹204.0030 Apr 2026
- 52-week low
- ₹126.1530 Mar 2026
- 1-year return
- −23.0%
- RSI (14-day)
- 38.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.76% | −5.9% | −13.3% | −18.4% | −23.0% |
Nath Bio-Genes (India) quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹32 Cr | ₹37 Cr | ₹52 Cr | ₹284 Cr | ₹44 Cr | ₹66 Cr | ₹52 Cr | ₹328 Cr |
| Revenue YoY | +42.6% | +16.2% | +20.7% | +16.3% | +36.2% | +78.9% | −0.7% | +15.8% |
| Net profit | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹37 Cr | ₹5 Cr | ₹2 Cr | −₹0 Cr | ₹32 Cr |
| Net profit YoY | −45.3% | −30.6% | −43.5% | +11.8% | +334.2% | −39.2% | −100.7% | −13.5% |
| Net margin | 3.4% | 7.2% | 2.8% | 13.1% | 11.0% | 2.4% | −0.0% | 9.8% |
| EPS | ₹0.53 | ₹1.33 | ₹0.42 | ₹19.58 | ₹1.40 | ₹0.84 | −₹0.79 | ₹16.98 |
Nath Bio-Genes (India) financials
| Item | FY13 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹138 Cr | ₹278 Cr | ₹301 Cr | ₹333 Cr | ₹365 Cr | — |
| Operating profit | ₹12 Cr | ₹25 Cr | ₹36 Cr | ₹38 Cr | ₹40 Cr | — |
| Net profit | ₹12 Cr | −₹67 Cr | ₹35 Cr | ₹40 Cr | ₹39 Cr | — |
| EPS (₹) | ₹7.00 | −₹36.00 | ₹18.00 | ₹20.00 | ₹20.00 | — |
| Cash from operations | ₹14 Cr | ₹17 Cr | ₹38 Cr | ₹75 Cr | ₹18 Cr | — |
| Total debt | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹5 Cr | ₹13 Cr | ₹17 Cr |
| Shareholders' equity | ₹57 Cr | ₹542 Cr | ₹573 Cr | ₹610 Cr | ₹644 Cr | ₹680 Cr |
Nath Bio-Genes (India) shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 45.60% | 45.60% | 45.60% | 45.60% | 45.60% | 45.60% |
| Foreign institutions | 0.21% | 0.42% | 0.32% | 0.31% | 0.23% | 0.27% |
| Domestic institutions | 3.94% | 2.25% | 0.76% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 50.25% | 51.74% | 53.32% | 54.08% | 54.17% | 54.13% |
| Promoter shares pledged | 16.38% | 13.78% | 13.78% | 13.78% | 13.78% | 13.78% |
Nath Bio-Genes (India) vs peers
The listed Pharma & Healthcare companies nearest to Nath Bio-Genes (India) by market capitalisation.
Ask anything about Nath Bio-Genes (India)
Pivot answers on the live chart with evidence you can check, and tests strategies against NATHBIOGEN's own history. Try: “Why has NATHBIOGEN moved over the last three months?” · “Backtest a 50-day moving-average crossover on NATHBIOGEN over five years” · “Compare NATHBIOGEN with ESPIRE on margins and valuation”
Frequently asked questions about Nath Bio-Genes (India)
What is the share price of Nath Bio-Genes (India) today?
Nath Bio-Genes (India) (NSE: NATHBIOGEN) last closed at ₹132.60 on 22 Oct 2026. Its 52-week high is ₹204.00 and its 52-week low is ₹126.15.
What is the market cap of Nath Bio-Genes (India)?
Nath Bio-Genes (India)'s market capitalisation is ₹252 Cr (₹252 Cr) at the 22 Oct 2026 close, ranking 2138th among the NSE companies Pivot tracks.
What is the P/E ratio of Nath Bio-Genes (India)?
Nath Bio-Genes (India) trades at a trailing P/E of 6.3.
What is the ROE and ROCE of Nath Bio-Genes (India)?
Return on equity was 6.1% in FY26 and return on capital employed was 8.0% in FY26 (consolidated figures).
Is Nath Bio-Genes (India) a debt-free company?
No. Nath Bio-Genes (India)'s debt-to-equity ratio was 0.2 in FY26, with total debt of ₹17 Cr.
What were Nath Bio-Genes (India)'s latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Nath Bio-Genes (India) reported revenue of ₹328 Cr, +15.8% year on year, and net profit of ₹32 Cr, −13.5% year on year.
How has Nath Bio-Genes (India) stock performed over the last year?
Nath Bio-Genes (India)'s share price has fallen 23.0% over the past year, −18.4% over three months and −13.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Nath Bio-Genes (India)?
As of 30 Jun 2026: promoters 45.60%, foreign institutions 0.27%, domestic institutions 0.01%, non-institutions 54.13%. 13.78% of promoter shares were pledged.
Who are Nath Bio-Genes (India)'s competitors?
The listed Pharma & Healthcare companies closest to Nath Bio-Genes (India) by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Gennex Labs, Kerala Ayur and BDH Industries.
Is Nath Bio-Genes (India) a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Nath Bio-Genes (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NATHBIOGEN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text